Skip to main content
Journal cover image

Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes.

Publication ,  Journal Article
D'Alessio, D; Häring, H-U; Charbonnel, B; de Pablos-Velasco, P; Candelas, C; Dain, M-P; Vincent, M; Pilorget, V; Yki-Järvinen, H ...
Published in: Diabetes Obes Metab
February 2015

AIM: To compare safety and efficacy of insulin glargine and liraglutide in patients with type 2 diabetes (T2DM). METHODS: This randomized, multinational, open-label trial included subjects treated for T2DM with metformin ± sulphonylurea, who had glycated haemoglobin (HbA1c) levels of 7.5-12%. Subjects were assigned to 24 weeks of insulin glargine, titrated to target fasting plasma glucose of 4.0-5.5 mmol/L or liraglutide, escalated to the highest approved clinical dose of 1.8 mg daily. The trial was powered to detect superiority of glargine over liraglutide in percentage of people reaching HbA1c <7%. RESULTS: The mean [standard deviation (s.d.)] age of the participants was 57 (9) years, the duration of diabetes was 9 (6) years, body mass index was 31.9 (4.2) kg/m(2) and HbA1c level was 9.0 (1.1)%. Equal numbers (n = 489) were allocated to glargine and liraglutide. Similar numbers of subjects in both groups attained an HbA1c level of <7% (48.4 vs. 45.9%); therefore, superiority of glargine over liraglutide was not observed (p = 0.44). Subjects treated with glargine had greater reductions of HbA1c [-1.94% (0.05) and -1.79% (0.05); p = 0.019] and fasting plasma glucose [6.2 (1.6) and 7.9 (2.2) mmol/L; p < 0.001] than those receiving liraglutide. The liraglutide group reported a greater number of gastrointestinal treatment-emergent adverse events (p < 0.001). The mean (s.d.) weight change was +2.0 (4.0) kg for glargine and -3.0 (3.6) kg for liraglutide (p < 0.001). Symptomatic hypoglycaemia was more common with glargine (p < 0.001). A greater number of subjects in the liraglutide arm withdrew as a result of adverse events (p < 0.001). CONCLUSION: Adding either insulin glargine or liraglutide to subjects with poorly controlled T2DM reduces HbA1c substantially, with nearly half of subjects reaching target levels of 7%.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Diabetes Obes Metab

DOI

EISSN

1463-1326

Publication Date

February 2015

Volume

17

Issue

2

Start / End Page

170 / 178

Location

England

Related Subject Headings

  • Treatment Outcome
  • Middle Aged
  • Metformin
  • Male
  • Liraglutide
  • International Cooperation
  • Insulin, Long-Acting
  • Insulin Glargine
  • Hypoglycemic Agents
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
D’Alessio, D., Häring, H.-U., Charbonnel, B., de Pablos-Velasco, P., Candelas, C., Dain, M.-P., … EAGLE Investigators, . (2015). Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes. Diabetes Obes Metab, 17(2), 170–178. https://doi.org/10.1111/dom.12406
D’Alessio, D., H. -. U. Häring, B. Charbonnel, P. de Pablos-Velasco, C. Candelas, M. -. P. Dain, M. Vincent, V. Pilorget, H. Yki-Järvinen, and H. EAGLE Investigators. “Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes.Diabetes Obes Metab 17, no. 2 (February 2015): 170–78. https://doi.org/10.1111/dom.12406.
D’Alessio D, Häring H-U, Charbonnel B, de Pablos-Velasco P, Candelas C, Dain M-P, et al. Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes. Diabetes Obes Metab. 2015 Feb;17(2):170–8.
D’Alessio, D., et al. “Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes.Diabetes Obes Metab, vol. 17, no. 2, Feb. 2015, pp. 170–78. Pubmed, doi:10.1111/dom.12406.
D’Alessio D, Häring H-U, Charbonnel B, de Pablos-Velasco P, Candelas C, Dain M-P, Vincent M, Pilorget V, Yki-Järvinen H, EAGLE Investigators. Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes. Diabetes Obes Metab. 2015 Feb;17(2):170–178.
Journal cover image

Published In

Diabetes Obes Metab

DOI

EISSN

1463-1326

Publication Date

February 2015

Volume

17

Issue

2

Start / End Page

170 / 178

Location

England

Related Subject Headings

  • Treatment Outcome
  • Middle Aged
  • Metformin
  • Male
  • Liraglutide
  • International Cooperation
  • Insulin, Long-Acting
  • Insulin Glargine
  • Hypoglycemic Agents
  • Humans